<DOC>
	<DOCNO>NCT01150812</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability AZD8165 pharmacokinetics metabolite AZ12971554 plasma level prodrug AZD8165 escalate single oral low dos .</brief_summary>
	<brief_title>Oral AZD8165 After Single Oral Ascending Doses Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Suitable vein cannulation repeat venipuncture Have body mass index ( BMI ) 19 30 kg/m2 weigh least 50 kg 100 kg History clinically significancy disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug Personal family history bleeding disorder , reasonable suspicion vascular malformation , include aneurysm .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>First time man</keyword>
	<keyword>healthy</keyword>
	<keyword>thrombin inhibitor</keyword>
</DOC>